Show simple item record

Impact of COVID-19 on patients with PiZZ alpha1-antitrypsin deficiency: the IMCA1 study revisited.

dc.contributor.authorChorostowska-Wynimko, Joanna
dc.contributor.authorCorsico, Angelo
dc.contributor.authorEsquinas, Cristina
dc.contributor.authorMcelvaney, Gerard
dc.contributor.authorSark, Annelot
dc.contributor.authorSucena, Maria
dc.contributor.authorTanash, Hanan
dc.contributor.authorTurner, Alice
dc.contributor.authorMiravitlles, Marc
dc.contributor.authorPARR, DAVID
dc.date.accessioned2023-11-02T10:33:17Z
dc.date.available2023-11-02T10:33:17Z
dc.date.issued2023-10-27
dc.identifier.citationEuropean Respiratory Journal 2023 62: PA5107en_US
dc.identifier.doi10.1183/13993003.congress-2023.pa5107
dc.identifier.pii10.1183/13993003.congress-2023.PA5107
dc.identifier.urihttp://hdl.handle.net/20.500.14200/2761
dc.description.abstractIMCA1 concluded that a poor outcome in patients with an AAT level <60mg/dl related to non-respiratory comorbidities more than to markers of respiratory disease1, but deaths only occurred in PiZZ patients.en_US
dc.language.isoenen_US
dc.publisherEuropean Respiratory Societyen_US
dc.sourceRespiratory infections and bronchiectasis
dc.subjectRespiratory medicineen_US
dc.titleImpact of COVID-19 on patients with PiZZ alpha1-antitrypsin deficiency: the IMCA1 study revisited.en_US
dc.typeConference Output
dc.source.journaltitleEuropean Respiratory Journal
rioxxterms.versionNAen_US
dc.contributor.trustauthorPARR, DAVID
dc.contributor.departmentMedicineen_US
dc.contributor.roleMedical and Dentalen_US
oa.grant.openaccessnaen_US


This item appears in the following Collection(s)

Show simple item record